Spinal Cord Injury Clinical Trial
Official title:
Insulin Sensitivity in the Peri-Wound Microcirculation of Pressure Ulcers in SCI
Verified date | August 2018 |
Source | James J. Peters Veterans Affairs Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Pressure ulcers (PU) are skin breakdowns that often form after blood flow in the skin is
reduced from prolonged and repeated exposure to externally applied forces. As many as 85% of
individuals with a spinal cord injury (SCI) report the occurrence of at least 1 PU since
being injured. Despite the increasing attention and emphasis on prevention, PUs still
represent a major health risk for persons with SCI. Among the numerous potential physical
risk factors identified for the development of a PU were several conditions that have a
significant negative effect on skin blood flow. In addition, improper management of blood
sugar is a major risk factor for PU development and it impedes healing. It would appear that
hormones (i.e., chemical signals in the blood) associated with how the body uses sugar that
target the blood vessels may play an important role in the development and formation of a PU.
In persons with SCI, skin blood flow responses to insulin (i.e., a hormone that helps the
body use sugar and also relaxes the blood vessels allowing blood flow to increase) in the
lower extremity were shown to be much lower than healthy individuals.
The proposed study in up to 30 individuals with chronic SCI and a difficult-to-heal pelvic
region PU has 2 phases: (1) a 4-week "observation" phase [if the PU does not heal
appropriately (determined by digital photos and software computation), and the subject is
found to be insulin resistant then they will progress to the next phase of the study] and (2)
an 8-week "treatment" phase. All participants will continue to receive the standard wound
care throughout the observation and treatment phases. If the surface area of the PU does not
decrease by more than 30% during the 4-week observation phase, the participant will be
eligible to enter the 8-week treatment phase, in which they will be randomly assigned to
receive active drug (e.g., pioglitazone) or placebo. The participants will have four study
visits in which the following will be acquired: digital image of the wound to monitor wound
surface area, skin blood flow measurements of the peri-wound area, and blood tests to monitor
liver function, kidney function, blood sugar (hemoglobin A1C, insulin, glucose), nutritional
status (albumin and pre-albumin), a complete blood count with differential, and makers of
inflammation. Weekly monitoring of symptoms and participant experiences will be closely
monitored.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | April 1, 2018 |
Est. primary completion date | April 1, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 79 Years |
Eligibility |
Inclusion Criteria: 1. Male or female, age 18 to 79; 2. Chronic (e.g., duration of injury at least 6 months), stable SCI (regardless of level of neurological lesion); 3. American Spinal Injury Association Impairment Scale (AIS) designation of A, B or C; and 4. At least one Stage III or IV PU in the pelvic region (e.g., ischial, trochanteric, perineal, and sacral regions) that has not shown signs of healing for a period of at least 1 month. 5. Hemoglobin A1C <7.0% Exclusion Criteria: 1. Persons who are candidates for or elect to have reconstructive flap surgery of the PU; 2. Hemoglobin A1C =7.0% 3. Psychopathology (documentation in the medical record or history of self-abusive behavior specific to PU healing which may or may not include major or minor psychiatric illness (that may conflict with the study objectives; 4. Previously diagnosed active malignant disease; 5. Suspicion of skin cancer at the PU site (i.e., clinical evaluation is currently on-going); 6. Life expectancy less than 12 months; 7. Nephrosis, hemodialysis or chronic ambulatory peritoneal dialysis therapy; 8. Acute illness or systemic infection (including MRSA); 9. Current pharmacological treatment for diabetes mellitus or insulin resistance with exogenous insulin (or its synthetic dialogues), insulin-sensitizing agents, or agents that alter pancreatic secretion of insulin; 10. Current pharmacological treatment with sympathomimetic agents demonstrating direct vascular actions or indirect implications (e.g., alpha-1 agonists, cholinesterase inhibitors, norepinephrine, calcium channel blockers, angiotensin converting enzymes); 11. Moderate to high dose glucocorticoid administrations (i.e., = 40 mg prednisone or equivalent steroid dose) within the past 3 months; 12. Atherosclerosis, congestive heart failure, or recent history of myocardial infarction (<90 months); 13. Previous diagnosis of diabetes mellitus or insulin resistance; 14. Diminished mental capacity; 15. Inability or unwillingness of subject to provide informed consent; or 16. Pregnancy or women who may become pregnant during the course of the study, or those who are nursing. |
Country | Name | City | State |
---|---|---|---|
United States | James J. Peters VA Medical Center | Bronx | New York |
Lead Sponsor | Collaborator |
---|---|
James J. Peters Veterans Affairs Medical Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Reliability of laser speckle contrast analysis imaging to detect meaningful interventional change in cutaneous peri-wound perfusion to pioglitazone treatment. | To determine the reliability of laser speckle contrast analysis imaging to detect meaningful interventional change in cutaneous peri-wound perfusion to pioglitazone treatment. | Before and After 8 Week Treatment with Pioglitazone | |
Primary | Skin Perfusion Response to Insulin Administered by Iontophoresis to the Cutaneous Peri-Wound region of a Chronic Region Pressure Ulcer before and after treatment with Pioglitazone | To determine the perfusion response to insulin administered by iontophoresis to the cutaneous peri-wound region of a chronic pelvic region pressure ulcer before and after treatment with pioglitazone (30 mg/d x 8 weeks). | Before and After 8 Week Treatment with Pioglitazone | |
Secondary | Association between the therapeutic effects of pioglitazone on the homeostatic model assessment of insulin resistance (HOMA-IR) and cutaneous peri-wound perfusion response to transdermal insulin administration. | To determine the association between the therapeutic effects of pioglitazone on the homeostatic model assessment of insulin resistance (HOMA-IR) and cutaneous peri-wound perfusion response to transdermal insulin administration. | Before and After 8 Week Treatment with Pioglitazone |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02574572 -
Autologous Mesenchymal Stem Cells Transplantation in Cervical Chronic and Complete Spinal Cord Injury
|
Phase 1 | |
Recruiting |
NCT05941819 -
ARC Therapy to Restore Hemodynamic Stability and Trunk Control in People With Spinal Cord Injury
|
N/A | |
Completed |
NCT05265377 -
Safety and Usability of the STELO Exoskeleton in People With Acquired Brain Injury and Spinal Cord Injury
|
N/A | |
Recruiting |
NCT02331979 -
Improving Bladder Function in SCI by Neuromodulation
|
N/A | |
Completed |
NCT02777281 -
Safe and Effective Shoulder Exercise Training in Manual Wheelchair Users With SCI
|
N/A | |
Recruiting |
NCT02978638 -
Electrical Stimulation for Continence After Spinal Cord Injury
|
N/A | |
Completed |
NCT02262234 -
Education Interventions for Self-Management of Pain Post-SCI: A Pilot Study
|
Phase 1/Phase 2 | |
Withdrawn |
NCT02237547 -
Safety and Feasibility Study of Cell Therapy in Treatment of Spinal Cord Injury
|
Phase 1/Phase 2 | |
Completed |
NCT02161913 -
Comparison of Two Psycho-educational Family Group Interventions for Persons With SCI and Their Caregivers
|
N/A | |
Terminated |
NCT02080039 -
Electrical Stimulation of Denervated Muscles After Spinal Cord Injury
|
N/A | |
Completed |
NCT01642901 -
Zoledronic Acid in Acute Spinal Cord Injury
|
Phase 3 | |
Completed |
NCT01884662 -
Virtual Walking for Neuropathic Pain in Spinal Cord Injury
|
N/A | |
Completed |
NCT01471613 -
Lithium, Cord Blood Cells and the Combination in the Treatment of Acute & Sub-acute Spinal Cord Injury
|
Phase 1/Phase 2 | |
Terminated |
NCT01433159 -
Comparison of HP011-101 to Standard Care for Stage I-II Pressure Ulcers in Subjects With Spinal Cord Injury
|
Phase 2 | |
Completed |
NCT02149511 -
Longitudinal Morphometric Changes Following SCI
|
||
Completed |
NCT01467817 -
Obesity/Overweight in Persons With Early and Chronic Spinal Cord Injury (SCI)
|
N/A | |
Completed |
NCT00663663 -
Telephone Intervention for Pain Study (TIPS)
|
N/A | |
Completed |
NCT01086930 -
Early Intensive Hand Rehabilitation After Spinal Cord Injury
|
Phase 3 | |
Completed |
NCT01025609 -
Dietary Patterns and Cardiovascular (CVD) Risk in Spinal Cord Injury (SCI) Factors In Individuals With Chronic Spinal Cord Injury
|
||
Terminated |
NCT01005615 -
Patterned Functional Electrical Stimulation (FES) Ergometry of Arm and Shoulder in Individuals With Spinal Cord Injury
|
Phase 1/Phase 2 |